Literature DB >> 22396620

Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages.

Andrew Baird1, Raul Coimbra, Xitong Dang, Nicole Lopez, Jisook Lee, Michael Krzyzaniak, Robert Winfield, Bruce Potenza, Brian P Eliceiri.   

Abstract

We identified fresh human leukocytes as an abundant source of the candidate epithelial tumor suppressor gene, Ecrg4, an epigenetically regulated gene, which unlike other tumor suppressor genes, encodes an orphan-secreted, ligand-like protein. In human cell lines, Ecrg4 gene expression was low, Ecrg4 protein undetectable, and Ecrg4 promoter hypermethylation high (45-90%) and reversible by the methylation inhibitor 5-AzaC. In contrast, Ecrg4 gene expression in fresh, normal human PBMCs and PMNs was 600-800 times higher than in cultured cell lines, methylation of the Ecrg4 promoter was low (<3%), and protein levels were readily detectable in lysates and on the cell surface. Flow cytometry, immunofluorescent staining, and cell surface biotinylation established that full-length, 14-kDa Ecrg4 was localized on PMN and monocyte cell surfaces, establishing that Ecrg4 is a membrane-anchored protein. LPS treatment induced processing and release of Ecrg4, as detected by flow and immunoblotting, whereas an effect of fMLF treatment on Ecrg4 on the PMN cell surface was detected on the polarized R2 subpopulation of cells. This loss of cell surface Ecrg4 was associated with the detection of intact and processed Ecrg4 in the conditioned media of fresh leukocytes and was shown to be associated with the inflammatory response that follows severe, cutaneous burn injury. Furthermore, incubation of macrophages with a soluble Ecrg4-derived peptide increased the P-p65, suggesting that processing of an intact sentinel Ecrg4 on quiescent circulating leukocytes leads to processing from the cell surface following injury and macrophage activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396620      PMCID: PMC3336773          DOI: 10.1189/jlb.1011503

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  41 in total

Review 1.  Limiting inflammatory responses during activation of innate immunity.

Authors:  Jiahuai Han; Richard J Ulevitch
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

2.  Enhanced expression of the human chitinase 3-like 2 gene (YKL-39) but not chitinase 3-like 1 gene (YKL-40) in osteoarthritic cartilage.

Authors:  Eric Steck; Stephen Breit; Steffen J Breusch; Matthias Axt; Wiltrud Richter
Journal:  Biochem Biophys Res Commun       Date:  2002-11-22       Impact factor: 3.575

3.  Esophageal cancer related gene 4 (ECRG4) is a marker of articular chondrocyte differentiation and cartilage destruction.

Authors:  Yun Hyun Huh; Je-Hwang Ryu; Sun Shin; Dong-Uk Lee; Siyoung Yang; Kyung-Shin Oh; Churl-Hong Chun; Jeong-Keun Choi; Woo Keun Song; Jang-Soo Chun
Journal:  Gene       Date:  2009-09-06       Impact factor: 3.688

4.  Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia.

Authors:  Janesh Pillay; Bart P Ramakers; Vera M Kamp; Adele Lo Tam Loi; Siu W Lam; Falco Hietbrink; Luke P Leenen; Anton T Tool; Peter Pickkers; Leo Koenderman
Journal:  J Leukoc Biol       Date:  2010-04-16       Impact factor: 4.962

5.  Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.

Authors:  Yoichiro Mori; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Horoki Kurehara; Ryota Mori; Keisuke Tomoda; Ryo Ogawa; Takeyasu Katada; Koshiro Harata; Yoshitaka Fujii
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

6.  Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor.

Authors:  E Decoster; B Vanhaesebroeck; P Vandenabeele; J Grooten; W Fiers
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

7.  Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo.

Authors:  Lin-Wei Li; Xi-Ying Yu; Yang Yang; Chun-Peng Zhang; Li-Ping Guo; Shih-Hsin Lu
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

8.  Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma.

Authors:  Chun-Mei Yue; Da-Jun Deng; Mei-Xia Bi; Li-Ping Guo; Shih-Hsin Lu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

9.  Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury.

Authors:  Ana Maria Gonzalez; Sonia Podvin; Shuh-Yow Lin; Miles C Miller; Hannah Botfield; Wendy E Leadbeater; Andrew Roberton; Xitong Dang; Stuart E Knowling; Elena Cardenas-Galindo; John E Donahue; Edward G Stopa; Conrad E Johanson; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Fluids Barriers CNS       Date:  2011-01-18

10.  Chemotactic peptide modulation of actin assembly and locomotion in neutrophils.

Authors:  T H Howard; W H Meyer
Journal:  J Cell Biol       Date:  1984-04       Impact factor: 10.539

View more
  23 in total

Review 1.  Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.

Authors:  Rui Zhou; Yuanshu Liu; Wenjun Huang; Xitong Dang
Journal:  Front Med       Date:  2019-08-29       Impact factor: 4.592

2.  Monitoring Neutrophil-Expressed Cell Surface Esophageal Cancer Related Gene-4 after Severe Burn Injury.

Authors:  Todd W Costantini; Raul Coimbra; Nicole E Lopez; Jeanne G Lee; Bruce Potenza; Alan Smith; Andrew Baird; Brian P Eliceiri
Journal:  Surg Infect (Larchmt)       Date:  2015-10-13       Impact factor: 2.150

3.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

4.  Soluble purified recombinant C2ORF40 protein inhibits esophageal cancer cell proliferation by inducing cell cycle G1 phase block.

Authors:  Xiaoyan Li; Linwei Li; Wenyu Wang; Yang Yang; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2015-06-26       Impact factor: 2.967

5.  The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury.

Authors:  Ashkaun Shaterian; Steven Kao; Lin Chen; Luisa A DiPietro; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Arch Dermatol Res       Date:  2012-08-17       Impact factor: 3.017

6.  Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation.

Authors:  Jisook Lee; Xitong Dang; Alexandra Borboa; Raul Coimbra; Andrew Baird; Brian P Eliceiri
Journal:  Neuro Oncol       Date:  2014-11-05       Impact factor: 12.300

7.  The Orphan C2orf40 Gene is a Neuroimmune Factor in Alzheimer's Disease.

Authors:  Sonia Podvin; Miles C Miller; Ryan Rossi; Jasmine Chukwueke; John E Donahue; Conrad E Johanson; Andrew Baird; Edward G Stopa
Journal:  JSM Alzheimers Dis Relat Dement       Date:  2016-04-01

8.  Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling.

Authors:  Tetsuo Moriguchi; Shun Kaneumi; Shuji Takeda; Kei Enomoto; Shyam Kumar Mishra; Tetsuro Miki; Uichi Koshimizu; Hidemitsu Kitamura; Toru Kondo
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

9.  Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Xiaoyan Li; Wenyu Wang; Tianhui Gao; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

Review 10.  ECRG4: a new potential target in precision medicine.

Authors:  Xin Qin; Ping Zhang
Journal:  Front Med       Date:  2018-07-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.